Microwave-Accelerated Metal Enhanced Fluorescence (MAMEF) of CT and GC

CT 和 GC 的微波加速金属增强荧光 (MAMEF)

• 批准号: 8872078
• 负责人: CHARLOTTE Ann GAYDOS
• 金额: $ 10.2万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE COUNTY
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-07-06 至 2017-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8872078
• 关键词: Archives; Award; Bacillus (bacterium); Baltimore; Bedside Testings; Biological Assay; Biological Sciences; Books; Care Technology Points; Chlamydia trachomatis; Clinic; Clinical; Collaborations; County; Data Analyses; Detection; Development; Diagnostic tests; Disease; Electrons; Evaluation; Female; Fluorescence; Fluorescent Probes; Funding; Gold; Grant; Head; Health; Healthcare; Human; Individual; Infection; Institutes; Legal patent; Location; Maryland; Medical center; Metals; National Institute of Biomedical Imaging and Bioengineering; Neisseria gonorrhoeae; Paper; Patients; Pediatric Hospitals; Peer Review; Phase; Photons; Predictive Value; Preparation; Prospective Studies; Publications; Publishing; RNA; Race; Recruitment Activity; Research; Research Personnel; Salmonella; Sampling; Sensitivity and Specificity; Sexually Transmitted Diseases; Shipping; Ships; Speed; Subgroup; Surface; Swab; Technology; Testing; Time; Treatment Cost; United States National Institutes of Health; Universities; Vagina; Validation; Woman; age group; base; chromophore; clinical research site; cost; health care delivery; improved; microwave electromagnetic radiation; nanoparticle; new technology; novel; point of care; professor; public health relevance

 DESCRIPTION (provided by applicant): Over the last several years the Institute of Fluorescence (IoF) at the University of Maryland Baltimore County has developed a fundamental technology which has the potential to profoundly change Point-of-Care testing and subsequently specific Human Health diseases. Our studies of the Microwave-Accelerated Metal-Enhanced Fluorescence technology (MAMEF), when applied to RNA- target assay sensing platforms, Salmonella Serovar targets, Bioagent targets such as Bacillus Anthraces and sexually transmitted Infections (STI's), is providing for the equivalent of PCR-level sensitivity, but without any thermal cyclic amplification steps, detecting as low as 1cfu/ml of bacterial target within 20 seconds. Not only does the MAMEF technology look set to seriously compete with PCR amplification approaches, but the combined speed, sensitivity and upfront sample preparation steps which we have developed to date, are allowing the technology to be seriously considered in Point-of-Care (POC) settings, where both sample preparation and target detection can be remarkably achieved within 1 minute. To the best of our knowledge, there is no other published technology which offers both the combined speed, sensitivity, low cost and the ability to be readily applied to numerous clinical targets. During the last 5 years, the Institute of Fluorescence was invited to participate in a trial study of our rapid and sensitive MAMEF technology, with the NIH's (NIBIB) POCTRN group. NIBIB created the national Point-of-Care Technologies Research Network (POCTRN) to drive the development of selected technologies through collaborations that merge scientific and technological capabilities with clinical need. The network was comprised of 4 world renowned centers, which span the USA, each with an individual research and health care delivery theme. Based on a highly successful evaluation phase of the MAMEF technology, NIBIB has continued to fund the MAMEF technology for the detection of STI's (Sexually Transmitted Infections) through one of these centers; a subaward from a Johns Hopkins University U54 STI Center grant, U54 EB007958, headed by Dr Charlotte Gaydos, a world renown STI researcher. While the U54 center grant has funded the development of the actual technology itself, with a limited testing phase, the funds are not available for a large scale prospective study and clinical validation. Subsequently, this R03 proposal is specifically focused at blindly clinically validating the MAMEF CT and GC assays developed under the U54 center grant, with 1800 female patients, over a 2 year period. The significance of a successful validation of the MAMEF technology in a clinical setting cannot be over stated. The MAMEF technology has the potential to directly impact STI testing and health care.

 描述（由适用提供）：在过去的几年中，马里兰州巴尔的摩县的荧光研究所（IOF）开发了一项基本技术，有可能深刻改变护理点测试以及随后特定的人类健康疾病。 Our studies of the Microwave-Accelerated Metal-Enhanced Fluorescence technology (MAMEF), when applied to RNA- target assay Sensing platforms, Salmonella Serovar targets, Bioagent targets such as Bacillus Anthraces and sexually transmitted Infections (STI's), is providing for the equivalent of PCR-level sensitivity, but without any thermal cyclic amplification steps, detecting as low as 1CFU/mL细菌靶标 在20秒内。 MAMEF技术不仅会与PCR扩增方法进行认真的竞争，而且我们迄今为止开发的合并速度，灵敏度和前期样本准备步骤都可以在1分钟内认真考虑样品准备和目标检测，从而可以在1分钟内认真考虑该技术。据我们所知，没有其他发表的技术既可以提供速度，灵敏度，低成本和容易应用于众多临床目标的能力。在过去的五年中，邀请荧光研究所与NIH（Nibib）Poctrn组一起参加我们快速和敏感的MAMEF技术的试验研究。 Nibib创建了国家护理技术研究网络（POCTRN），以通过将科学和技术能力与临床需求合并的合作来推动所选技术的开发。 网络完成了4个跨越美国的世界知名中心，每个中心都有一个个人的研究和医疗服务主题。基于MAMEF技术的非常成功的评估阶段，Nibib继续为MAMEF技术提供资金，以通过这些中心之一检测STI（性传播感染）；约翰·霍普金斯大学U54 STI中心赠款的一个子宣告，U54 EB 007958，由世界著名的STI研究员夏洛特·盖多斯博士领导。尽管U54中心赠款已经资助了实际技术本身的开发，但测试阶段有限，但这些资金不可用于大规模的前瞻性研究和临床验证。随后，该R03提案专门针对盲目临床验证U54中心拨款下开发的MAMEF CT和GC分析，并在2年内拥有1800名女性患者。在临床环境中成功验证MAMEF技术的重要性不能过度说明。 MAMEF技术有可能直接影响STI测试和医疗保健。